SU5416 in Treating Patients With Advanced or Recurrent Cancer of the Head and Neck
RATIONALE: SU5416 may stop the growth of cancer cells by stopping blood flow to the tumor.
PURPOSE: Phase II trial to study the effectiveness of SU5416 in treating patients who have advanced or recurrent cancer of the head and neck.
Carcinoma of Unknown Primary
Head and Neck Cancer
Non-melanomatous Skin Cancer
|Study Design:||Primary Purpose: Treatment|
|Official Title:||A Phase II Trial of SU5416 (NSC #696819) in Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck|
|Study Start Date:||December 2000|
|Primary Completion Date:||January 2003 (Final data collection date for primary outcome measure)|
- Determine the effect of SU5416 on survival and tumor response in patients with advanced or recurrent squamous cell carcinoma of the head and neck.
- Determine the safety and toxicity of SU5416 in these patients.
OUTLINE: Patients receive SU5416 IV over 1 hour twice weekly. Treatment continues in the absence of disease progression or unacceptable toxicity.
Patients are followed for 1 year.
PROJECTED ACCRUAL: A total of 35 patients will be accrued for this study within 1.4 years.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00006361
|United States, New York|
|Memorial Sloan-Kettering Cancer Center|
|New York, New York, United States, 10021|
|Study Chair:||David G. Pfister, MD||Memorial Sloan-Kettering Cancer Center|